AMRX (Amneal) Future Price to Earnings

Official company branding of Amneal (AMRX)

Amneal Pharmaceuticals (AMRX) maintains its status as a reliable supplier of affordable biosimilars. However, pricing pressure and debt limit its maneuverability, while environmental measures remain formal. The company's forward P/E valuation reflects market expectations, where 17.30 serves as the final level marker. This chart's current trend is comparable to product realization rates amid regulatory requirements.

amneal.com - AMRX Market Cap to Future Earnings Ratio (period 07/04/2022 - 11/17/2026)

Summary analytical data breakdowns for amneal.com (AMRX)

Fundamental valuation:Amneal Pharmaceuticals, Inc.
Brand item of Amneal Pharmaceuticals

The search for defensive assets is based on identifying undervaluation relative to future earnings, which is critical for Amneal Pharmaceuticals (AMRX) and its portfolio of generics and proprietary drugs for endocrinology and infection therapy. By analyzing the issuer's forward P/E, an investor assesses the current share price through the lens of projected net income, where a declining ratio signals either an increase in the margin of safety or a systemic deterioration of the business's fundamental indicators.

Analysis of competing companies

Future Price to Earnings haleon.com (HLN)|KVUE (Kenvue Health) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|Perrigo - Market Cap to Future Earnings Ratio|ALVO: Forward P/E Multiple|Liquidia Technologies - Future Price to Earnings Multiple|GLPG (Galapagos N.V.) - Forward P/E Multiple|Projected Price to Earnings Ratio anipharmaceuticals.com ANIP|Future Price to Earnings MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Pacira BioSciences, Inc. PCRX|Forward P/E Multiple ARS Corp SPRY|Theravance Biopharma - Forward P/E Multiple|Forward Price to Earnings Multiple Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Future Price to Earnings|Projected Price to Earnings Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - Forward P/E Multiple|Price to Future Earnings Ratio SXTC (China SXT Pharmaceuticals)|Forward P/E Multiple EPRX|Forward P/E Multiple bioharvest.com (BHST)|Future Price to Earnings Invizyne Technologies EXOZ|ORMP: Price to Future Earnings Ratio|ENTX: Projected Price to Earnings|HYFT: Future Price to Earnings|ABVC BioPharma Inc. (ABVC) - Future Price to Earnings|cumberlandpharma.com (CPIX) - Forward P/E Multiple|QNTM (Quantum BioPharma) - Forward P/E Multiple|FGEN: Future Price to Earnings Multiple|Forward P/E Multiple TELO|Forward P/E Multiple Rani Therapeutics Holdings (RANI)|Forward P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Projected Price to Earnings Ratio|LEXX - Future Price to Earnings|PULM (Pulmatrix) - Price to Future Earnings Ratio|Pheton Holdings Ltd (PTHL) - Future Price to Earnings|Aptorum - Future Price to Earnings Multiple|Projected Price to Earnings LYRA|Projected Price to Earnings Impact BioMedical Inc (IBO)|Forward P/E Multiple TNFA|YCBD: Price to Expected Earnings Ratio|Future Price to Earnings PainReform PRFX|altamiratherapeutics.com (CYTO) - Projected Price to Earnings Ratio|LIPO: Projected Price to Earnings|OPTN (optinose.com) - Price to Future Earnings Ratio|PIRS: Forward P/E Multiple|PROC - Market Cap to Projected Earnings|PTPI (Petros Pharma) - Forward P/E Multiple|Future Price to Earnings QLI|Forward P/E Multiple SLRN|Market Cap to Future Earnings Ratio TFFP